在HLA - A24 +非小细胞肺癌患者中鉴定出可被细胞免疫和体液免疫反应识别的表皮生长因子受体衍生肽。

Identification of epidermal growth factor receptor-derived peptides recognised by both cellular and humoral immune responses in HLA-A24+ non-small cell lung cancer patients.

作者信息

Shomura Hiroki, Shichijo Shigeki, Komatsu Nobukazu, Matsueda Satoko, Mine Takashi, Rikimaru Toru, Sato Yuji, Todo Satoru, Itoh Kyogo

机构信息

Department of Immunology, School of Medicine, Research Center of Innovative Cancer Therapy of the 21st Century COE Program for Medical Science, Kurume University, 67 Asahi-machi, Kurume, Fukuoka 830-0011, Japan.

出版信息

Eur J Cancer. 2004 Jul;40(11):1776-86. doi: 10.1016/j.ejca.2004.04.003.

DOI:10.1016/j.ejca.2004.04.003

PMID:15251169

Abstract

The epidermal growth factor receptor (EGFR) is one of the most appropriate target molecules for cancer therapy because of its high expression in epithelial cancers. A novel EGFR-tyrosine-kinase inhibitor, ZD1839, has been approved as a drug for non-small cell lung cancer (NSCLC), and many other agents are now being tested in clinical trials. Cytotoxic T lymphocyte (CTL)-directed epitope peptides could be another class of useful compounds in EGFR-targeted therapies. However, at present, there are no data on CTL-directed peptides of EGFR. Therefore, this study aimed to identify immunogenic EGFR-derived peptides in HLA-A24(+) NSCLC patients. We report in this study three such EGFR-derived peptides at positions 54-62, 124-132 and 800-809. These peptides were recognised by both cellular and humoral immune responses in most of the peripheral blood mononuclear cells (PBMCs) and sera from NSCLC patients that we tested. These results may provide a scientific basis for the development of EGFR-based immunotherapy.

摘要

表皮生长因子受体（EGFR）因其在上皮癌中的高表达，是癌症治疗中最合适的靶分子之一。一种新型EGFR酪氨酸激酶抑制剂ZD1839已被批准用于非小细胞肺癌（NSCLC）治疗，目前许多其他药物正在临床试验中接受测试。细胞毒性T淋巴细胞（CTL）导向的表位肽可能是EGFR靶向治疗中的另一类有用化合物。然而，目前尚无关于EGFR的CTL导向肽的数据。因此，本研究旨在鉴定HLA - A24(+) NSCLC患者中具有免疫原性的EGFR衍生肽。我们在本研究中报告了位于54 - 62、124 - 132和800 - 809位的三种此类EGFR衍生肽。在我们测试的大多数NSCLC患者的外周血单个核细胞（PBMC）和血清中，这些肽被细胞免疫和体液免疫反应所识别。这些结果可能为基于EGFR的免疫治疗的发展提供科学依据。